|

27 Publicly-Traded Psychedelic Stocks Investors Have Their Eyes On

Publicly-Traded Psychedelic Stocks

Thinking about investing in psychedelics? Experts say it could be a  smart move. Researchers have been exploring the benefits of psychedelics for decades. And the research is showing promise; these substances appear to treat a number of mental health issues better than some conventional therapies.

“Decades of research have demonstrated that psychedelics, which are hallucinogenic drugs, are effective in treating mental disorders such as depression, suicidal thoughts, PTSD and anxiety,” Ellen Chang wrote in U.S. News and World Report. “The Food and Drug Administration has approved and fast-tracked several clinical research trials.”

Tania Gonsalves, analyst for Canaccord Genuity Capital Markets, notes that the market value for psychedelic therapies — which are less costly than conventional drug-based treatments — could be as high as $100 billion. She says the companies that will dominate the market “will have deep pockets, patentable products and a well-thought-out reimbursement strategy.”

Legislation and the decriminalization of psychedelics is moving the needle ahead as well. Oregon became the first state to legalize psychedelics in clinical settings as well as decriminalizing personal use and possession. Cities including Denver, Washington D.C., Ann Arbor, Mich., and Oakland and Santa Cruz in California have all passed similar decriminalization laws.

But it isn’t just the U.S. making psychedelics a ripe investing platform. The EU is seeing research and product expansion as is Canada. This list of companies shows a strong presence in the Canadian market.

Public Psychedelic Companies (alphabetical)

1. Aion Therapeutic (CSE:AION), Toronto, Ontario

It’s currently a cannabis company, but plans include crossing over into psychedelics,

2. Atai Life Sciences (NASDAQ: ATAI), Berlin, Germany

A biopharmaceutical company working with a number of substances to treat mental health issues. Its psilocybin-based drug was as effective as the antidepressant Lexapro in clinical trials.

3. Better Plant Sciences (CSE:PLNT,OTCQB:VEGGF), Vancouver, British Columbia

A wellness-focused firm that has taken a majority ownership stake in NeonMind Biosciences, which is working on psilocybin research.

4. Champignon Brands (CSE:SHRM,OTCQB:SHRMF) Port Moody, British Columbia

It’s working with a number of psychedelics and plans to open clinics for psychedelic treatments.

5. Clarify Pharma (AQSE: PSYC.PL.) London, England

An investment platform focused on biotech and life sciences companies with an interest in advancing psychedelic medicine.

6. Codebase Ventures (CSE:CODE,OTCQB:BKLLF), Vancouver, British Columbia

An investment firm with opportunities in psilocybin and microdose enterprise Titan Shrooms & Psychedelics.

7. Compass Pathways (NASDAQ:CMPS), United Kingdom

A research giant focused on depression treatments by way of psychedelics.

8. Field Trip Health (CSE:FTRP) Toronto, Ontario

With an app, ketamine clinics, and Dr. Andrew Weil now on its advisory board, Field Trip is normalizing psychedelic therapies.

9. Global Trac Solutions (OTC Pink: PSYC) San Diego, California

Integrating media, creativity, and technology around psychedelics, it owns and operates Psychedelic Spotlight.

10. Graph Blockchain (CSE:GBLC)Richmond, British Columbia

Its recent acquisition of Shroom Street puts it in position to combine tech and treatment.

11. GreenStar Biosciences (CSE:GSTR,OTC Pink:GTSIF), Vancouver, British Columbia

With the Eleusian Biosciences acquisitions it is expanding research and therapy options through a unique combination of N-Acetylcysteine and psilocybin.

12. Havn Life Sciences (CSE:HAVN) Vancouver, British Columbia

With an exemption from Health Canada, it’s able to research and develop psilocybin-based products for scientific use, developing compounds for natural health products.

13. Hollister Biosciences (CSE:HOLL,OTC Pink:HSTRF) Vancouver, British Columbia

While rooted in cannabis, Hollister acquired psilocybin-focused AlphaMind Brands. It’s working to develop natural health products.

14. Mind Medicine (MindMed) (NEO:MMED,OTCQB:MMEDF) Toronto, Ontario

Tackling opioid addiction with psychedelics is top priority for MindMed and it’s being hailed as one of the hottest stocks in the market after its recent partnership with Johns Hopkins.

15. Mydecine Innovations Group (CSE:MYCO) Vancouver, British Columbia

Mydecine Health Sciences, Mindleap Health, and NeuroPharm make up the group dedicated to developing psychedelic products for treating a variety of ailments.

16. Mynd Life Sciences (CSE: MYND) Vancouver, British Columbia

A pharmaceutical company focused on psychedelic drug development.

17. Neon Mind (CSE: NEON) Vancouver, British Columbia

A subsidiary of Better Plant Sciences Inc. working on psilocybin as a weight loss treatment. 

18. New Wave Holdings (CSE:SPOR) Toronto, Ontario

This investment firm is working with companies producing a recreational product line, cosmetics, as well as developing other medical-grade products.

19. Numinus (TSXV:NUMI) Vancouver, British Columbia

With a cannabis business already booming, it’s also exploring psychedelic therapies for treatments related to physical, mental and emotional health.

20. Nutritional High International (CSE:EAT,OTC Pink:SPLIF) Toronto, Ontario

Cannabis-heavy NHI is also researching psychedelics for use in weight loss, insomnia, anxiety, and pain management.

21. Red Light Holland (CSE:TRIP) Toronto, Canada

Canadian-based RLH is distributing legal recreational psilocybin truffles in the Netherlands.  

22. Revive Therapeutics (CSE:RVV,OTC Pink:RVV) Toronto, Ontario

Revive is looking at utilizing psilocybin in treating a number of health issues with cannabis and psilocybin.

23. Roadman Investments (TSXV:LITT) Vancouver, British Columbia

Roadman entered in a joint venture with Psychedelic Insights aimed at opening clinics to offer clinician-assisted psychedelic therapies.

24. Seelos Therapeutics (NASDAQ:SEEL) New York, New York

Seelos is working on ketamine treatments to avert suicidal behaviors and other serious mental health disorders.

25. Small Pharma (TSXV: DMT) London, England

A neuropharmaceutical company focused on the potent psychedelic DMT in alternative therapies for mental health treatment.

26. Thoughtful Brands (CSE:TBI,OTCQB:PEMTF) Vancouver, British Columbia

While heavily focused on cannabis, the company (formerly MOTA Ventures), is developing a psilocybin research hub in Germany.

27. Wesana Health (CSE: WESA) Toronto, Ontario

A psychedelic life sciences startup co-founded by former two-time Stanley Cup champion Daniel Carcillo, the company is focused on using psychedelic and naturally sourced therapies to treat traumatic brain injuries.

Similar Posts

  • Numinus’ BIG Patent, Mydecine Tackles A $13.6 BILLION Market & Some BUY Ratings! ( NUMI / MYCO)

    BIG news for Mydecine (MYCO : NEO) (MYCOF: OTC) and Numinus Wellness (NUMI: NEO)
    (LKYSF : OTC). But The BIGGER NEWS is that we are finally launching our website: https://thepsychedelicinvestor.com/, where we will be sharing the latest industry news for all of your favorite companies.
    We hope we can facilitate our community’s path to information about the psychedelic sector. We would like to invite you to share your opinions and suggestions down in the comment section.

    Last but not least, if you wish to collaborate and become a contributor for The Psychedelic Investor, you’re welcome to send us an email at thepsychedelicinvestor@gmail.com or fill in a form on our website! We welcome your opinion and you can have a shot at seeing your name in the opinion section of our website!

    Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!

    Links:

    Numinus Wellness (TSXV: NUMI, OTC: LKYSF), Filed a Patent Application for their Proprietary Rapid Production Process of Psilocybe Mushrooms and Other Psychoactive Fungi Species:
    https://thepsychedelicinvestor.com/2021/06/24/numinus-files-u-s-provisional-patent-application-for-a-proprietary-rapid-production-process-for-psilocybe-and-other-psychoactive-fungi-species/

    Mydecine (NEO: MYCO, OTC: MYCOF), Will Attempt To Treat Substance Use Disorder and Nicotine Addiction With Their MYCO-004 Molecule:
    https://thepsychedelicinvestor.com/2021/06/24/mydecine-selects-substance-use-disorder-and-smoking-cessation-for-novel-psychedelic-molecule-myco-004/

    Mydecine’s 4 Proprietary Compounds Advancing To Clinical Trials: Myco 001, 002, 003, 004:
    https://thepsychedelicinvestor.com/2021/04/07/mydecine-announces-four-lead-novel-drug-candidates-and-prepares-for-pre-ind-meetings-with-the-fda-and-health-canada-to-prepare-for-human-clinical/

    Johns Hopkins psilocybin study results:
    https://www.hopkinsmedicine.org/news/stories/mushrooms_quit_smoking.html

    Roth Capital Initiates Coverage On Mydecine Innovations with Buy Rating, Announces Price Target of 3$:
    https://www.benzinga.com/news/21/06/21664391/roth-capital-initiates-coverage-on-mydecine-innovations-with-buy-rating-announces-price-target-of-c

    Enjoy the episode!

    Timestamps:
    0:00 – Intro
    1:37- Numinus’ patent application to speed up their psilobe mushrooms’ production process
    4:53 – Mydecine announces it will use their MYCO – 004 molecule to treat substance use disorder and addiction
    9:15 – Roth Capital says that Mydecine is a BUY with a price target of $3

    Follow us on social media! 🙌
    Instagram: @thepsychedelicinvestor
    Facebook: @thepsychedelicinvestor

    Want to collaborate? Send us an email at:
    thepsychedelicinvestor@gmail.com

    Music from:
    www.bensound.com

    Video editing: @themyaholy

    Check out our Benziga discounts
    https://benzinga.grsm.io/jameshallifax1834
    https://benzinga.grsm.io/thepsychedelicinvestor

    DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

    All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

    #Numinus #Mydecine #NUMIStock

  • MindMed Financial Results & Business Update Q2 2021 ( Where Does MNMD/MMED Go From Here?)

    MindMed’s Financial Results & Business Update for Q2 2021 are out!
    In this episode, we’ll discuss MindMed, ( MMED: NEO), (MNMD: NASDAQ), (MMQ: FRA), who recently announced their Q2 financials and gave a business update.
    This was an important, transitional quarter for the company for several reasons.

    First, and perhaps most significantly, during Q2, co-founder JR Rahn stepped down as CEO, being replaced by Robert Barrow, who was previously Chief Development Officer.

    Second, in terms of progress in the mission to heal mental health, MindMed made several strides in this quarter, which we’ll discuss today.

    Pertinent links:

    MindMed’s CEO Jr Rahn Steps Down:
    https://thepsychedelicinvestor.com/2021/06/09/mindmed-announces-chief-executive-officer-transition/

    Project Angie Update:
    https://mindmed.co/news/press-release/mindmed-announces-project-angie-targeting-the-treatment-of-pain-with-psychedelics/

    MindMed’s Collaboration with NextStage Therapeutics:
    https://mindmed.co/news/press-release/mindmed-announces-launch-of-collaboration-with-nextage-therapeutics-brain-targeting-liposome-system/

    MindMed’s Pharmacogenetic Study:
    https://thepsychedelicinvestor.com/2021/05/26/mindmed-and-liechti-lab-in-basel-switzerland-publish-first-pharmacogenetic-data-on-lsd-to-help-guide-personalized-dosing/

    MMED’s Q2 Financial Results & Business Update:
    https://thepsychedelicinvestor.com/2021/08/13/mindmed-announces-2021-q2-financial-results-cash-balance-of-157-usd-million-195-cad-million-to-execute-on-diverse-clinical-pipeline/

    Enjoy the episode!

    Follow us on social media! 🙌
    Instagram: @thepsychedelicinvestor
    Facebook: @thepsychedelicinvestor

    Want to collaborate? Send us an email at:
    thepsychedelicinvestor@gmail.com

    Music from:
    www.bensound.com

    Video editing: @themyaholy

    Check out our Benziga discounts
    https://benzinga.grsm.io/jameshallifax1834
    https://benzinga.grsm.io/thepsychedelicinvestor

    DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

    All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

    #MindMed #MindMedStock #MNMD